Pricing and Financial Pressures - The company is facing pricing pressures due to cost containment measures in the U.S. and other countries, including a volume-based procurement program in China that resulted in unsuccessful bids[96] - Group purchasing organizations are negotiating pricing arrangements, which may limit the company's ability to sell products to affiliated members if not selected[98] - The company has experienced downward pressure on product pricing and other effects of healthcare reform in international markets, which could adversely affect its financial condition and cash flows[99] - Inflation has increased the overall cost structure, potentially affecting liquidity and financial condition[120] - A 10% price change in raw material commodities would not have a material effect on the company's consolidated financial position, results of operations, or cash flows[260] Debt and Financial Obligations - The company incurred $595.0 million in floating rate indebtedness and prepaid $275.0 million on the term loan, with $221.9 million outstanding as of December 31, 2024[108] - The company has $221.9 million of floating rate debt, and a hypothetical 100 basis points increase in SOFR would raise annual interest expense by $2.2 million[261] - The company does not expect to pay cash dividends for the foreseeable future, as it intends to retain future earnings for business operations and expansion[169] Inventory and Supply Chain Risks - The company is exposed to risks of excess and obsolete inventory, which may adversely impact cash flow and liquidity[116] - The company has entered into supply contracts for raw materials with terms of 12 to 24 months to mitigate commodity price fluctuations[260] International Operations and Currency Risks - Approximately 41% of the company's net sales in 2024 were derived from international markets, indicating a significant reliance on global operations[124] - A significant portion of foreign revenues is generated in Europe and Japan, making the company vulnerable to currency exchange rate fluctuations[117] - The company is exposed to foreign currency exchange rate risks primarily with Euros, Japanese Yen, Canadian Dollars, and Swiss Francs, and manages this risk through derivative financial instruments[259] Regulatory and Compliance Challenges - The company is subject to income taxes in the U.S. and various foreign jurisdictions, with ongoing audits that could materially affect financial statements[121] - The company is subject to stringent FDA regulations for medical devices, which can delay product approvals and impact financial results[131] - Compliance with the EU MDR, effective since May 2021, requires significant expenses and could delay marketing approvals for products in the EU[135] - The company is exposed to healthcare fraud and abuse laws, which could result in substantial penalties and affect business operations[137] - Data privacy and security laws, including the EU GDPR, impose significant compliance costs and potential liabilities for the company[142] - Compliance with new or changing laws related to data protection could result in substantial civil and/or criminal penalties, adversely impacting the business and financial condition[144] Operational and Technological Risks - Implementation of new enterprise resource planning (ERP) systems has caused disruptions, impacting operating results in 2022, with potential for similar issues in 2025 and beyond[100] - The company is increasingly dependent on sophisticated information technology, and failure to maintain or protect information systems could adversely affect operations[146] - Cyber-attack attempts are becoming more frequent and sophisticated, posing risks to business operations and reputation[149] Legal and Environmental Risks - The company bears the risk of warranty claims on products, which could exceed warranty reserves and harm financial condition[150] - Intellectual property rights are crucial for the company, and failure to protect these rights could result in significant monetary damages and impact product sales[151] - The company is involved in various legal proceedings that could result in adverse outcomes, potentially harming financial results[154] - The business involves the use of hazardous materials, and compliance with environmental laws may incur significant costs and restrict operations[156] - Climate change poses risks to operations from natural disasters, which could increase operational costs and impact supply chains[157] Market and Stock Performance - The market price of the company's common stock may be volatile, influenced by various factors including operating results and market conditions[167] - Analysts' research and reports significantly influence the trading market for the company's common stock, and unfavorable reports could lead to a decline in stock price[164] - The company has significant credit risk concentrations in public and private hospitals and dental practices, particularly in Europe, which are subject to government budget constraints[263] Foreign Regulatory and Trade Risks - The company faces risks from changes in foreign regulatory requirements, currency fluctuations, and trade barriers that could increase operating costs[125] - Zimmer Biomet may require indemnification for additional taxes resulting from acquisitions, which could materially impact the company's financial results[162]

Exhibit 99.1 ZimVie Reports Fourth Quarter and Full Year 2024 Financial Results PALM BEACH GARDENS, Florida, February 26, 2025 (GLOBE NEWSWIRE) – ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental market, today reported financial results for the quarter and year ended December 31, 2024. Management will host a corresponding conference call today, February 26, 2025, at 4:30 p.m. Eastern Time. "2024 was a transformational year for ZimVie. We became a pure play dental companyand reshaped ou ...

Core Insights - ZimVie Inc. reported a transformational year in 2024, becoming a pure play dental company and reducing net debt by over $290 million [2] - The company achieved an increase in Adjusted EBITDA margins by over 4 percentage points in Q4 2024 compared to Q4 2023, despite a softer end market [2] - ZimVie is optimistic about the long-term growth drivers in the dental implant market, supported by successful training and education programs [2] Financial Performance - Q4 2024 - Third-party net sales for Q4 2024 were $111.5 million, a decrease of 1.4% on a reported basis and 0.9% in constant currency compared to Q4 2023 [3] - The net loss for Q4 2024 was $(9.7) million, an improvement of $12.5 million from a net loss of $(22.2) million in Q4 2023 [4] - Adjusted net income for Q4 2024 was $7.6 million, an increase of $5.0 million from Q4 2023 [4] Financial Performance - Full Year 2024 - Total third-party net sales for the full year 2024 were $449.7 million, a decrease of 1.6% on a reported basis and 1.2% in constant currency compared to 2023 [6] - The net loss for the full year 2024 was $(33.8) million, an improvement of $22.2 million from a net loss of $(56.0) million in 2023 [7] - Adjusted EBITDA for the full year 2024 was $60.0 million, or 13.3% of third-party net sales, an increase of $9.2 million from 2023 [8] Financial Guidance for 2025 - Projected net sales for FY2025 are expected to be between $445 million and $460 million, reflecting a growth of (1%) to 2% [11] - Adjusted EBITDA for FY2025 is projected to be between $65 million and $70 million, indicating an increase of 8% to 17% [11] - Adjusted EPS for FY2025 is expected to be between $0.80 and $0.95, representing a growth of 29% to 53% [11] Company Overview - ZimVie Inc. is a global leader in the dental market, focusing on developing and delivering products for dental tooth replacement and restoration procedures [13] - The company aims to improve smiles and confidence through its comprehensive portfolio, including dental implants and digital workflow solutions [13]

Core Viewpoint - ZimVie Inc. will report its financial results for Q4 and full-year 2024 on February 26, 2025, after market close, followed by a conference call at 4:30 p.m. Eastern Time [1]. Company Overview - ZimVie is a global leader in the dental market, focusing on developing, manufacturing, and delivering a comprehensive portfolio of products for dental tooth replacement and restoration [2]. - The company is headquartered in Palm Beach Gardens, Florida, and operates additional facilities worldwide, aiming to enhance smiles, function, and confidence through its dental solutions [2]. - ZimVie offers a range of products including dental implants, biomaterials, and digital workflow solutions, and is committed to advancing clinical science and technology in the dental field [2].

Core Insights - ZimVie Inc. has published a scientific study indicating that its premium dental implants may reduce the risk of peri-implant infections compared to other implants available in the market [1][2][3] Group 1: Study Findings - The study, published in the Journal of Biomedical Materials Research, evaluated ZimVie's dual acid-etched coronal surface technology against other leading implant brands [2] - The research highlights a critical threshold roughness for implant surfaces, where rougher surfaces increase bacterial adhesion, while ZimVie's implants maintain adhesion levels comparable to smooth machined surfaces [3] - ZimVie's Contemporary Hybrid Surface technologies are designed to mitigate the rising prevalence of peri-implant mucositis and peri-implantitis [3] Group 2: Product Information - TSX Implants, launched in 2022, are engineered for immediate extraction and standard loading protocols, focusing on primary stability and crestal bone maintenance [4] - T3 PRO Implants, also launched in 2022, feature a hybrid surface design that promotes high primary stability and immediate function, with clinical studies supporting their safety and performance [5] Group 3: Company Overview - ZimVie is a global leader in the dental market, dedicated to developing and delivering a comprehensive range of products for dental tooth replacement and restoration [7] - The company operates from its headquarters in Palm Beach Gardens, Florida, and aims to enhance patient outcomes through advanced clinical science and technology [7]

Financial Performance - Total net sales for the three months ended September 30, 2024, were $103.2 million, a decrease of 2.0% compared to $105.3 million in the same period of 2023[84]. - For the nine months ended September 30, 2024, total net sales were $338.2 million, down 1.8% from $344.4 million in 2023[85]. - The company experienced a price decline of 1.1% in net sales for the nine months ended September 30, 2024, primarily due to pricing pressures in North America and China[85][87]. - Foreign exchange fluctuations had a small positive effect on year-over-year sales for the three months ended September 30, 2024, mainly due to the strengthening of the Euro[88]. Expenses - Research and development expenses increased to 6.7% of net sales in the three months ended September 30, 2024, compared to 5.4% in the same period of 2023[92]. - Selling, general and administrative expenses rose to 55.5% of net sales in the three months ended September 30, 2024, up from 53.7% in the prior year[89]. - Cost of products sold as a percentage of net sales decreased to 34.7% in the three months ended September 30, 2024, from 35.0% in the same period of 2023[89]. - Restructuring and other cost reduction initiatives recognized expenses of $0.7 million in the three months ended September 30, 2024, compared to $1.4 million in the same period of 2023[95]. Cash Flow and Liquidity - Cash and cash equivalents were $68.1 million as of September 30, 2024, down from $87.8 million at the end of 2023[103]. - Cash flows from operating activities were $(7.3) million for the nine months ended September 30, 2024, compared to $15.7 million in the same period of 2023[104]. - Cash flows from investing activities were $285.2 million for the nine months ended September 30, 2024, primarily from the sale of the spine segment[105]. - Cash flows used in financing activities were $295.4 million for the nine months ended September 30, 2024, including a $275.0 million prepayment on the Term Loan[106]. - The company believes available cash and cash equivalents will be sufficient to meet liquidity needs for at least the next 12 months[108]. Debt and Interest - As of September 30, 2024, the company had $221.9 million of floating rate debt subject to SOFR, with a potential $2.2 million decrease in annual pre-tax results from a 100 basis points increase in SOFR[113]. - Interest income increased due to the promissory note from the sale of the spine segment[98]. - Interest expense decreased due to a reduction in outstanding debt and interest rates[99]. Legal Matters - The company is subject to various claims and legal proceedings, but does not expect a material adverse impact on results of operations, cash flows, or financial position[119]. - The outcome of legal matters is unpredictable and could have a material adverse effect on financial position, results of operations, or cash flows[119]. Other Significant Events - The company recorded a gain of $11.3 million from the sale of its spine segment, which was completed on April 1, 2024, for a total purchase price of $377.2 million[75]. - The company initiated restructuring activities in January 2024 to better support its dental segment following the sale of the spine segment[80]. - Other income related to TSA income was $3.2 million and $6.6 million for the three and nine months ended September 30, 2024 and 2023, respectively[97]. - The effective tax rate (ETR) on loss before income taxes was 18.4% for Q3 2024 compared to (3.3%) for Q3 2023[100]. - There were no changes in internal control over financial reporting during the three months ended September 30, 2024[117].

Financial Performance - Third party net sales for Q3 2024 were $103.2 million, a decrease of 2.0% on a reported basis and 2.2% in constant currency compared to Q3 2023[3]. - Net loss for Q3 2024 was $(3.0) million, an improvement of $7.2 million from a net loss of $(10.2) million in Q3 2023, with a net loss margin of 3.0%[4]. - Adjusted EBITDA for Q3 2024 was $13.1 million, representing a margin of 12.7%, an increase of $0.9 million or 110 basis points from Q3 2023[5]. - Adjusted net income for Q3 2024 was $3.3 million, an increase of $2.1 million compared to Q3 2023[4]. - Adjusted diluted EPS for Q3 2024 was $0.12, while basic and diluted EPS were $(0.11)[5]. - The net loss margin improved by 670 basis points from 9.7% in Q3 2023 to 3.0% in Q3 2024[4]. - The company reported a basic loss per share from continuing operations of $(0.11) for the three months ended September 30, 2024, compared to $(0.38) for the same period in 2023[17]. - Adjusted Net Income for the three months ended September 30, 2024, was $3,283 thousand, resulting in a Diluted EPS of $0.12, compared to a Diluted EPS of $(0.38) in 2023[22]. Sales and Revenue - Total net sales for the three months ended September 30, 2024, were $103,222, a decrease of 2.0% compared to $105,311 for the same period in 2023[17]. - U.S. Dental Net Sales for the nine months ended September 30, 2024, were $202,414 thousand, down 0.9% from $204,173 thousand in 2023[20]. - International Dental Net Sales for the three months ended September 30, 2024, decreased by 6.0% to $37,872 thousand from $40,308 thousand in 2023[20]. - Total Third Party Sales for the nine months ended September 30, 2024, were $338,228 thousand, down 1.7% from $344,131 thousand in 2023[24]. - The company reported a Constant Currency % Change in Total Dental Net Sales of (2.2%) for the three months ended September 30, 2024[20]. Guidance and Projections - The company updated its full-year 2024 guidance, projecting net sales of $450 million to $455 million and adjusted EBITDA of $60 million to $62 million[5]. Expenses and Costs - Cost of products sold for Q3 2024 was $(35,820) thousand, a decrease from $(36,907) thousand in Q3 2023, representing a 2.9% reduction[25]. - Adjusted cost of products sold, excluding intangible asset amortization, was $(35,533) thousand in Q3 2024, compared to $(36,614) thousand in Q3 2023, reflecting a 2.9% decrease[25]. - Research and development expenses for Q3 2024 totaled $(6,926) thousand, up from $(5,677) thousand in Q3 2023, indicating an increase of 22.1%[25]. - Selling, general and administrative expenses for Q3 2024 were $(57,313) thousand, slightly higher than $(56,505) thousand in Q3 2023, a 1.4% increase[25]. - The percentage of adjusted cost of products sold to net sales for Q3 2024 was 34.4%, slightly lower than 34.8% in Q3 2023[25]. Cash Flow and Assets - Cash and cash equivalents decreased to $66,808 as of September 30, 2024, from $71,511 as of December 31, 2023[18]. - Total assets decreased to $782,948 as of September 30, 2024, from $1,205,345 as of December 31, 2023[18]. - Net cash used in operating activities for the nine months ended September 30, 2024, was $(7,276), compared to $15,694 for the same period in 2023[19]. Company Strategy and Investments - The company is focusing on operational improvements and has made investments in sales force, R&D initiatives, and training programs for future expansion[2]. - The company is committed to advancing clinical science and technology in the dental market, focusing on product development and market expansion[7]. Other Financial Metrics - The company incurred $(20,285) thousand in research and development expenses for the nine months ended September 30, 2024, compared to $(19,365) thousand in the same period of 2023, an increase of 4.7%[25]. - The company reported a net impact of $(476) thousand from share-based compensation modification in Q3 2024, compared to no such expense in Q3 2023[25].

Core Viewpoint - ZimVie Inc. will report its financial results for Q3 2024 on October 30, 2024, after market close, with a conference call scheduled for 4:30 p.m. Eastern Time [1]. Company Overview - ZimVie is a global leader in the dental market, focusing on developing, manufacturing, and delivering a comprehensive portfolio of products for dental tooth replacement and restoration [2]. - The company is headquartered in Palm Beach Gardens, Florida, and operates additional facilities worldwide, aiming to enhance smiles, function, and confidence through its dental solutions [2]. - ZimVie offers a range of products, including dental implants, biomaterials, and digital workflow solutions, and is committed to advancing clinical science and technology in the dental field [2].

Core Insights - The Mexican spinal implant and vertebral compression fracture (VCF) market was valued at over $135 million in 2023 and is projected to grow at a CAGR of 6.1%, exceeding $205 million by 2030 [1][3]. Market Overview - The report covers various segments including cervical fixation devices, thoracolumbar fixation devices, interbody devices, motion preservation devices, VCF treatment, electrical stimulation devices, and spinal surgery instrumentation [2][6]. - The market analysis includes unit sales, average selling prices, market value, and growth trends, with projections extending to 2030 and historical data from 2020 [3][7]. Market Trends - There is a growing interest in minimally invasive surgery (MIS) in Mexico, which is gaining popularity due to shorter recovery times and fewer complications, although its adoption is still behind more advanced markets [3]. - The healthcare system in Mexico is primarily hospital-focused, resulting in a lower rate of outpatient procedures compared to other Latin American countries, which poses challenges for the adoption of advanced surgical technologies [4]. Competitive Landscape - ZimVie/Highridge Medical is the market leader in 2023, holding significant shares in cervical fixation, thoracolumbar fixation, and interbody device segments, supported by a strong distribution network [5]. - Medtronic ranks as the second-largest player, leading in the VCF segment with its PVA device, while DePuy Synthes is third, primarily generating revenue from fixation devices [5]. Market Segmentation - Cervical fixation devices include anterior and posterior types, while thoracolumbar fixation devices are categorized based on degenerative treatments and approaches [6]. - Interbody devices encompass various types such as ALIF, PLIF, and expandable devices, while motion preservation devices include artificial discs and dynamic stabilization [6]. Research Scope - The report covers the Mexican market with a base year of 2023 and a forecast period from 2024 to 2030, including quantitative and qualitative analyses of market size, procedure volume, and competitive dynamics [7][8].

Financial Data and Key Metrics Changes - Total revenue for Q2 2024 was $117 million, reflecting a decrease of 1.5% in reported rates and a modest decline of 0.4% in constant currency [11][12] - Adjusted EBITDA for Q2 2024 was $16.1 million, representing a margin of 13.8% [14] - Adjusted earnings per share for Q2 2024 was $0.13 on a fully diluted share count of 27.4 million shares [14] Business Line Data and Key Metrics Changes - The dental implant portfolio saw strong traction with new products, contributing to market share gains [4][5] - Biomaterials offerings experienced modest growth, outpacing market growth, indicating potential future growth for implant offerings [7] - The digital portfolio grew high single digits, driven by over 20% growth in the Implant Concierge service [8][10] Market Data and Key Metrics Changes - U.S. third-party net sales for Q2 2024 were $69.3 million, a slight increase of 0.1% [11] - Outside the U.S., third-party net sales were $47.5 million, a decrease of 3.8% on a reported basis [12] - The Asia Pacific market showed a reported decline of 6.9%, but grew 1.1% in constant currency, indicating stability in certain regions like Japan and India [39] Company Strategy and Development Direction - The company aims to enhance its premium dental implant market position while expanding its digital capabilities [20] - Focus on innovation in product offerings, including the introduction of GenTek Restorative Components and partnerships with Medit for imaging solutions [6][9] - The strategy includes improving operational efficiency and achieving a 15% plus adjusted EBITDA margin by April 2025 [15][16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the execution and resilience of the portfolio despite market challenges [10][18] - The outlook for Q3 2024 anticipates a sequential decline in revenue due to seasonal impacts, with expected adjusted EBITDA margins around 12% [16][26] - Management remains cautious about market recovery, indicating that underlying challenges persist [26] Other Important Information - The company finalized the sale of its Spine business on April 1, 2024, which is reflected in discontinued operations [11] - Cash as of the end of Q2 2024 was $78.6 million, with gross debt approximately $235 million [15] Q&A Session Summary Question: Company positioning within dental market - Management highlighted the unique assets and premium positioning in the dental implant market, focusing on organic growth and potential complementary product categories [19][20] Question: Impact of iTero Lumina's restorative launch delay - Management acknowledged the delay's impact on 2024 projections, attributing missed digital sales primarily to scanner sales [22][23] Question: Q3 revenue guidance and market demand - Management indicated that Q3 is expected to be lower due to seasonal trends, with cautious optimism about patient demand stabilizing [25][26] Question: Insights from planning software and market trends - Management noted growth in guided surgery and biomaterials as leading indicators of market stabilization [32][33] Question: Strategic considerations regarding potential partnerships - Management emphasized the importance of maintaining differentiation and open strategies in the market, while being prepared for future opportunities [35][36] Question: Capacity and performance in Asia - Management reported minimal exposure to China, with positive growth in other Asia Pacific markets like India and Australia [38][39]